11,336 Shares in Natera, Inc. $NTRA Acquired by GSA Capital Partners LLP

GSA Capital Partners LLP purchased a new stake in Natera, Inc. (NASDAQ:NTRA) during the 2nd quarter, Holdings Channel.com reports. The institutional investor purchased 11,336 shares of the medical research company’s stock, valued at approximately $3,077,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. JPMorgan Chase & Co. lifted its holdings in shares of Natera by 10.5% during the fourth quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock valued at $2,944,800,000 after purchasing an additional 1,225,420 shares during the last quarter. Wellington Management Group LLP boosted its position in shares of Natera by 94.7% in the 4th quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock valued at $1,140,026,000 after purchasing an additional 2,420,263 shares during the period. State Street Corp increased its stake in Natera by 2.2% in the 3rd quarter. State Street Corp now owns 3,389,599 shares of the medical research company’s stock worth $545,624,000 after purchasing an additional 72,087 shares in the last quarter. Coatue Management LLC raised its holdings in Natera by 1,446.1% during the 4th quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock worth $603,270,000 after buying an additional 2,463,008 shares during the period. Finally, Geode Capital Management LLC raised its holdings in shares of Natera by 0.5% during the fourth quarter. Geode Capital Management LLC now owns 2,608,644 shares of the medical research company’s stock valued at $596,078,000 after acquiring an additional 11,689 shares during the period. Institutional investors and hedge funds own 99.90% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. Canaccord Genuity Group set a $375.00 price objective on shares of Natera in a research report on Friday, August 7th. Zacks Research upgraded Natera from a “strong sell” rating to a “hold” rating in a report on Wednesday. Robert W. Baird set a $348.00 target price on Natera in a research report on Friday, August 7th. Piper Sandler lifted their price target on Natera from $249.00 to $363.50 and gave the company an “overweight” rating in a report on Wednesday. Finally, Guggenheim upped their price target on Natera from $290.00 to $360.00 and gave the company a “buy” rating in a research report on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Natera has an average rating of “Moderate Buy” and a consensus target price of $319.38.

Insiders Place Their Bets

In related news, Director Roelof Botha sold 78,000 shares of Natera stock in a transaction on Monday, June 1st. The stock was sold at an average price of $220.31, for a total transaction of $17,184,180.00. Following the completion of the sale, the director owned 1,076,198 shares of the company’s stock, valued at approximately $237,097,181.38. This trade represents a 6.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Solomon Moshkevich sold 3,410 shares of the business’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $265.58, for a total value of $905,627.80. Following the completion of the transaction, the insider owned 129,019 shares in the company, valued at $34,264,866.02. This trade represents a 2.57% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 181,045 shares of company stock valued at $41,330,968 in the last three months. Company insiders own 5.05% of the company’s stock.

Natera Stock Performance

Shares of NTRA opened at $309.93 on Friday. The company’s 50 day moving average price is $263.76 and its 200 day moving average price is $226.40. Natera, Inc. has a 52 week low of $156.71 and a 52 week high of $326.03. The company has a market capitalization of $44.67 billion, a PE ratio of -227.89 and a beta of 1.51.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. The company had revenue of $752.75 million during the quarter, compared to the consensus estimate of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The company’s revenue was up 37.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.74) EPS. On average, equities analysts forecast that Natera, Inc. will post -1.11 earnings per share for the current fiscal year.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.